Parvovirus B19 IgG ELISA kit is an enzyme immunoassay for the in-vitro diagnostic quantitative and qualitative determination of IgG class antibodies against Parvovirus B19 in human serum and plasma. Parvovirus B19 IgG ELISA kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The wells of this Parvovirus B19 IgG ELISA kit are coated with antigen. Specific antibodies of the sample binding to the antigen coated wells are detected by a secondary enzyme conjugated antibody (E-Ab) specific for human IgG. After the substrate reaction the intensity of the color developed is proportional to the amount of IgG-specific antibodies detected. Results of samples can be determined directly using the standard curve.
The Parvovirus B19 IgG ELISA kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sunlight. The storage and stability of specimen and prepared reagents is stated in the protocol insert. The microtiter strips of this Parvovirus B19 IgG ELISA kit are stable up to 12 mon in the broken, but tightly closed bag when stored at 2–8°C. The test results using this Parvovirus B19 IgG ELISA kit are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards and kit controls used with this Parvovirus B19 IgG ELISA kit must be found within the acceptable ranges as stated on the QC Certificate. If the criteria are not met, the run is not valid and should be repeated. Each laboratory should use known samples as further controls.
The Parvovirus B 19 is the agent of the Erythema infectiosum (EI), also called "fifth disease", characterized by different symptoms ranging from an erythematous rash, febrile illness to severe arthritis/arthralgia and lymphadenopathy depending on the age of the patients. Parvovirus B 19 infects and lyses red cell progenitors and transiently interrupts the production of red cells. IgM antibodies can be determined in parallel to the onset of symptoms (12-17 days after exposure) and decrease between 30 and 60 days later. IgG antibodies increase from 2-5 days after onset of symptoms and persist for several years. Parvovirus B 19 infection in children often passes without symptoms or may be associated with low-fever. Some show an erythematous rash on the face or on the extremities, whereas B 19 infections in adults are often associated with severe symptoms like febrile illness or lymphadenopathy, self-limited arthritis and arthralgia. In persons requiring increased production of red cells to maintain normal cell volumes, like patients with chronic hemolytic anemias such as sickle cell disease, hereditary spherocytosis, ß-Thalassemia and autoimmune hemolytic anemia, B 19 may cause transient aplastic crisis (TAC). In immunocompromised persons like patients underlying chemotherapy, congenital immundeficieny or HIV infection, chronic infections can occur and cause a severe, persistent anemia. In pregnant women B 19 infection causes a hydrops fetalis in 5-10 % and leads to intrauterine fetal death in 9-13 %.
Download Product Data Sheet